Drug discovery for diabetic nephropathy: trying the leap from mouse to man.
Authors Breyer MD
Submitted By Matthew Breyer on 7/7/2015
Status Published
Journal Seminars in nephrology
Year 2012
Date Published 9/1/2012
Volume : Pages 32 : 445 - 451
PubMed Reference 23062985
Abstract Diabetic nephropathy is the single major cause of kidney failure in the
industrialized world and given the emerging global pandemic of diabetes
mellitus, its prevalence is expected to only increase. Because of the lack of
dynamic biomarkers that define the rate of kidney function loss, there are few
proof-of-concept clinical trials for new therapeutics to treat diabetic
nephropathy. A molecular understanding of the pathogenesis of diabetic
nephropathy also is lacking. These deficiencies are magnified by the fact that
most mouse models of diabetic nephropathy fail to show progressive kidney
disease. Recently, some mouse models that showed requisite phenotypic changes of
diabetic nephropathy have been identified. Validation of results obtained in
these experimental models, and showing whether they accurately can predict
clinical response to therapeutics in human diabetic nephropathy, must now be

Investigators with authorship
Matthew BreyerEli Lilly and Company